RAB27B Controls Palmitoylation-Dependent NRAS Trafficking and Signaling in Myeloid Leukemia
Jian-Gan Ren,Bowen Xing,Kaoshen Lv,Rachel A. O'Keefe,Mengfang Wu,Ruoxing Wang,Kaylyn M. Bauer,Arevik Ghazaryan,George M. Burslem,Jing Zhang,Ryan M. O'Connell,Vinodh Pillai,Elizabeth O. Hexner,Mark R. Philips,Wei Tong
DOI: https://doi.org/10.1172/jci165510
IF: 19.456
2023-01-01
Journal of Clinical Investigation
Abstract:RAS mutations are among the most prevalent oncogenic drivers in cancers. RAS proteins propagate signals only when associated with cellular membranes as a consequence of lipid modifications that impact their trafficking. Here, we discovered that RAB27B, a RAB family small GTPase, controlled NRAS palmitoylation and trafficking to the plasma membrane, a localization required for activation. Our proteomic studies revealed RAB27B upregulation in CBL- or JAK2-mutated myeloid malignancies, and its expression correlated with poor prognosis in acute myeloid leukemias (AMLs). RAB27B depletion inhibited the growth of CBL-deficient or NRAS-mutant cell lines. Strikingly, Rab27b deficiency in mice abrogated mutant but not WT NRAS-mediated progenitor cell growth, ERK signaling, and NRAS palmitoylation. Further, Rab27b deficiency significantly reduced myelomonocytic leukemia development in vivo. Mechanistically, RAB27B interacted with ZDHHC9, a palmitoyl acyltransferase that modifies NRAS. By regulating palmitoylation, RAB27B controlled c-RAF/MEK/ERK signaling and affected leukemia development. Importantly, RAB27B depletion in primary human AMLs inhibited oncogenic NRAS signaling and leukemic growth. We further revealed a significant correlation between RAB27B expression and sensitivity to MEK inhibitors in AMLs. Thus, our studies presented a link between RAB proteins and fundamental aspects of RAS posttranslational modification and trafficking, highlighting future therapeutic strategies for RAS-driven cancers.